LUM015

DRUG4 trials

Sponsors

David Kirsch, Lumicell, Inc.

Conditions

Breast CancerColorectal CancerEsophageal CancerGastric CancerNeoadjuvant TherapyPancreatic CancerSarcomaSoft Tissue Sarcoma

Phase 1

Cathepsin Activatable Fluorescent Probe

CompletedNCT01626066

David KirschBreast Cancer, Sarcoma, Soft Tissue Sarcoma

Start: 2012-06-30End: 2015-08-31Updated: 2015-12-09

Feasibility Study of Intraoperative Imaging in Breast Cancer

CompletedNCT02438358

Lumicell, Inc.Breast Cancer

Start: 2015-06-30End: 2017-10-31Updated: 2023-01-05

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

RecruitingNCT02584244

Lumicell, Inc.Colorectal Cancer, Esophageal Cancer, Gastric Cancer +1

Start: 2016-08-04End: 2027-04-01Target: 66Updated: 2026-01-16

Phase 2

Feasibility Study of Intraoperative Detection of Residual Cancer in Breast Cancer Patients

TerminatedNCT04440982

Lumicell, Inc.Breast Cancer, Neoadjuvant Therapy

Start: 2020-09-01End: 2024-02-29Updated: 2025-01-15

Related Papers

Abstract CT043: Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy

Cancer Research2023-04-14

Abstract OT2-07-01: Feasibility study to evaluate performance of the LUM Imaging System for intraoperative detection of residual tumor in breast cancer patients receiving and not receiving neoadjuvant therapy

Cancer Research2023-03-01

Abstract OT2-12-02: Feasibility study to evaluate performance of the LUM imaging system for intraoperative detection of residual tumor in patients with breast cancer receiving neoadjuvant therapy

Cancer Research2022-02-15

Abstract CT245: Feasibility study to evaluate performance of the Lum Imaging System for intraoperative detection of residual tumor in patients with breast cancer receiving neoadjuvant therapy

Cancer Research2021-07-01

Intraoperative lumpectomy cavity margin analysis with far-red fluorescence to reduce volume of tissue excised during breast cancer lumpectomy surgery.

Journal of Clinical Oncology2018-05-202 citations

A phase I study of the safety and activation of a cathepsin-activatable fluorescent cancer-specific probe LUM015.

Journal of Clinical Oncology2014-05-203 citations